Menarini launches anti-anginal Ranexa in UK and Germany
This article was originally published in Scrip
Executive Summary
CV Therapeutics and Menarini have launched their first-in class anti-anginal Ranexa (ranolazine extended-release tablets) in the UK and Germany, as an adjunctive therapy for patients with stable angina pectoris that are inadequately controlled or intolerant to first-line therapies.